Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.46 |
| ▸ | JAK1 | P23458 | 14/20 | 0.46 |
| ▸ | JAK3 | P52333 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20993693 | 0.91 | JAK2 (0.46) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL20993759 | 0.89 | JAK2 (0.43) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL2469774 | 0.89 | JAK2 (0.42) | JAK2JAK1JAK3TYK2 | |
| Hydrochloric Acid SCHEMBL14575572 | 0.89 | JAK2 (0.42) | JAK2JAK1JAK3TYK2 | |
| Hydrochloric Acid SCHEMBL14574915 | 0.89 | JAK2 (0.42) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19304418 | 0.88 | JAK2 (0.51) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL18677513 | 0.87 | JAK2 (0.44) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19304153 | 0.85 | JAK2 (0.47) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL19304207 | 0.85 | JAK2 (0.45) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL18700126 | 0.84 | JAK2 (0.44) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2023-02-09 | — | — | US | disclosed |
| US-11214573-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORPORATION | 2020-12-24 | — | — | US | disclosed |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-9999619-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE CORPORATION | 2017-08-31 | — | — | US | disclosed |
| US-9611269-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214573-B2 | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | JAK2 3/4885JAK1 1/4885JAK3 2/4885 |
| US-20200397774-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20170246157-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-20230043959-A1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.